BACKGROUND: The chemokine system plays an important role in the pathogenesis of acute rejection or atherosclerosis. Three polymorphisms in the promoter region of the chemokine RANTES (-403G/A, -28G/C, In1.1T/C) are associated with a different expression of this chemokine as well as the occurrence of cardiovascular disease. Therefore, we investigated the impact of these three polymorphisms on the outcome after renal transplantation. METHODS: In 261 patients receiving their first kidney transplant, we genotyped the RANTES promoter polymorphisms (-403G/A, -28G/C, In1.1T/C) by real-time PCR. RESULTS: For the RANTES -403G/A and for the intronic polymorphism In1.1T/C, we found a significantly higher rate of recurrent acute rejection episodes (-403G/A: 11.1 vs. 31.0%, In1.1T/C: 11.8 vs. 33.0%). For the overall rate of acute rejection, we observed no significant differences according to the RANTES promoter polymorphisms. The other tested variables (DGF, graft survival, renal function) were not associated with one of the three polymorphisms. CONCLUSION: Our data indicate a relevant role of RANTES in kidney transplantation, particularly for the occurrence of recurrent acute rejection. To clarify the role of the analysed polymorphisms for long-term survival, especially for the occurrence of cardiovascular events, larger studies in the future are needed.
BACKGROUND: The chemokine system plays an important role in the pathogenesis of acute rejection or atherosclerosis. Three polymorphisms in the promoter region of the chemokine RANTES (-403G/A, -28G/C, In1.1T/C) are associated with a different expression of this chemokine as well as the occurrence of cardiovascular disease. Therefore, we investigated the impact of these three polymorphisms on the outcome after renal transplantation. METHODS: In 261 patients receiving their first kidney transplant, we genotyped the RANTES promoter polymorphisms (-403G/A, -28G/C, In1.1T/C) by real-time PCR. RESULTS: For the RANTES-403G/A and for the intronic polymorphism In1.1T/C, we found a significantly higher rate of recurrent acute rejection episodes (-403G/A: 11.1 vs. 31.0%, In1.1T/C: 11.8 vs. 33.0%). For the overall rate of acute rejection, we observed no significant differences according to the RANTES promoter polymorphisms. The other tested variables (DGF, graft survival, renal function) were not associated with one of the three polymorphisms. CONCLUSION: Our data indicate a relevant role of RANTES in kidney transplantation, particularly for the occurrence of recurrent acute rejection. To clarify the role of the analysed polymorphisms for long-term survival, especially for the occurrence of cardiovascular events, larger studies in the future are needed.
Authors: William S Oetting; David P Schladt; Robert E Leduc; Pamala A Jacobson; Weihua Guan; Arthur J Matas; Ajay Israni Journal: Transpl Int Date: 2011-09-29 Impact factor: 3.782
Authors: William S Oetting; David P Schladt; Casey R Dorr; Baolin Wu; Weihua Guan; Rory P Remmel; David Iklé; Roslyn B Mannon; Arthur J Matas; Ajay K Israni; Pamala A Jacobson Journal: Transplantation Date: 2019-08 Impact factor: 4.939
Authors: Nancy A Wilson; James Dylewski; Kenna R Degner; Megan A O'Neill; Shannon R Reese; Luis G Hidalgo; Judith Blaine; Sarah E Panzer Journal: Transpl Immunol Date: 2019-12-27 Impact factor: 1.708
Authors: Elisabet Van Loon; Baptiste Lamarthée; Thomas Barba; Sandra Claes; Maarten Coemans; Henriette de Loor; Marie-Paule Emonds; Priyanka Koshy; Dirk Kuypers; Paul Proost; Aleksandar Senev; Ben Sprangers; Claire Tinel; Olivier Thaunat; Amaryllis H Van Craenenbroeck; Dominique Schols; Maarten Naesens Journal: Front Immunol Date: 2022-02-23 Impact factor: 7.561